Lipanthyl Nt (Fenofibrate (Nanonised))

Fenofibrate activates the nuclear receptor PPARα, which regulates genes involved in fatty‑acid oxidation and lipoprotein metabolism. This activation increases the breakdown of triglyceride‑rich particles, reduces hepatic production of very‑low‑density lipoprotein, and modestly raises HDL‑cholesterol, resulting in an overall improvement of the lipid profile.

The appropriate dose of Lipanthyl Nt is determined by the prescribing healthcare professional based on the patient’s clinical condition, laboratory results, and concomitant therapies. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Fenofibrate is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and risk assessment with their healthcare provider before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lipanthyl Nt. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with statins, fenofibrate primarily targets triglycerides and modestly raises HDL‑cholesterol, whereas statins mainly lower LDL‑cholesterol. In patients with mixed dyslipidaemia, fenofibrate can be used alone or in combination with statins to achieve broader lipid control, but the combination requires monitoring for muscle‑related adverse effects.

Lipanthyl Nt should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat, and direct sunlight to maintain stability and potency throughout the shelf life.

Lipanthyl Nt is taken orally, usually with a meal to enhance absorption. The tablet should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare professional.

The most serious risks include rhabdomyolysis or severe myopathy, especially when combined with statins or gemfibrozil, as well as acute liver injury, pancreatitis, and rare severe allergic reactions. Patients should promptly report unexplained muscle pain, dark urine, jaundice, or signs of an allergic response.

Lipanthyl Nt is contraindicated in patients with severe liver disease, active gallbladder disease, known hypersensitivity to fenofibrate or other fibrates, and in those with uncontrolled severe hypertriglyceridaemia (>1000 mg/dL). Caution is also advised for individuals with renal impairment or those taking interacting medications.